IAPP and metabolic dysfunction-associated steatohepatitis: We utilized a mouse model that had been fed the Amylin Liver NASH-promoting (AMLN) diet (Hernandez et al., 2019; Sun et al., 2022; Zhao et al., 2018), and examined the potential impact of liver-specific downregulation of FincoR on tropifexor’s effects on NASH pathology.